TOFACITINIB IN ULCERATIVE COLITIS: THE RELATIONSHIP BETWEEN OCTAVE INDUCTION WEEK 8 SYMPTOMATIC REMISSION AND OCTAVE SUSTAIN WEEK 52 REMISSION

Pierre Desreumaux  ¹     Filiz Akyüz  ²     Christina Ha  ³     Amira Bouzidi  ⁴     Amel Tamzali  ⁴     Sean Gardiner  ⁵     Joseph Wu  ⁶     Jerome Paulissen  ⁶     Lucine Vuitton  ⁷     Miguel Regueiro  ^8    
1 Lille University and Hospital, INFINITE, U1286, Inserm, France
² Division of Gastroenterohepatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
³ Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, AZ, United States
⁴ Pfizer Inc, Paris, France
⁵ Pfizer Inc, New York, NY, United States
⁶ Pfizer Inc, Groton, CT, United States
⁷ University Hospital of Besançon, University Bourgogne-Franche-Comté, 25030 Besançon, France
⁸ Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, United States

Topic
IBD

Session
PP 05 IBD (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)